Bristi Basu

3.8k total citations
85 papers, 1.5k citations indexed

About

Bristi Basu is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Bristi Basu has authored 85 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 54 papers in Oncology, 25 papers in Molecular Biology and 25 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Bristi Basu's work include Pancreatic and Hepatic Oncology Research (16 papers), Ovarian cancer diagnosis and treatment (14 papers) and Cancer Genomics and Diagnostics (11 papers). Bristi Basu is often cited by papers focused on Pancreatic and Hepatic Oncology Research (16 papers), Ovarian cancer diagnosis and treatment (14 papers) and Cancer Genomics and Diagnostics (11 papers). Bristi Basu collaborates with scholars based in United Kingdom, United States and France. Bristi Basu's co-authors include Pippa Corrie, Johann S. de Bono, L. Rhoda Molife, Bhawna Sirohi, Víctor Moreno, Stan B. Kaye, M. Puglisi, Timothy A. Yap, Nick Carroll and Jon Emery and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Bristi Basu

85 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Bristi Basu United Kingdom 21 817 638 307 249 161 85 1.5k
Theresa L. Werner United States 24 779 1.0× 501 0.8× 271 0.9× 247 1.0× 198 1.2× 99 1.7k
Sharad Ghamande United States 22 770 0.9× 579 0.9× 216 0.7× 230 0.9× 169 1.0× 114 1.7k
Ramona F. Swaby United States 22 1.1k 1.3× 621 1.0× 278 0.9× 289 1.2× 316 2.0× 83 1.8k
Yoshiyasu Nakamura Japan 25 528 0.6× 650 1.0× 325 1.1× 398 1.6× 231 1.4× 71 1.6k
Ashiq Masood United States 17 574 0.7× 485 0.8× 308 1.0× 366 1.5× 94 0.6× 54 1.2k
Dagmar Hess Switzerland 20 897 1.1× 880 1.4× 267 0.9× 368 1.5× 117 0.7× 61 1.7k
Jane Robertson United Kingdom 22 1.3k 1.6× 816 1.3× 283 0.9× 510 2.0× 121 0.8× 57 2.0k
Stephen Welch Canada 24 1.0k 1.3× 626 1.0× 279 0.9× 388 1.6× 79 0.5× 124 1.9k
Emmanuel Blot France 19 639 0.8× 543 0.9× 368 1.2× 207 0.8× 71 0.4× 50 1.4k
Ruth Board United Kingdom 23 1.0k 1.2× 732 1.1× 656 2.1× 441 1.8× 134 0.8× 57 1.9k

Countries citing papers authored by Bristi Basu

Since Specialization
Citations

This map shows the geographic impact of Bristi Basu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bristi Basu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bristi Basu more than expected).

Fields of papers citing papers by Bristi Basu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bristi Basu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bristi Basu. The network helps show where Bristi Basu may publish in the future.

Co-authorship network of co-authors of Bristi Basu

This figure shows the co-authorship network connecting the top 25 collaborators of Bristi Basu. A scholar is included among the top collaborators of Bristi Basu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bristi Basu. Bristi Basu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
González-Martı́n, Antonio, Hyun Cheol Chung, Esma Saâda-Bouzid, et al.. (2024). Lenvatinib plus pembrolizumab for patients with previously treated advanced ovarian cancer: Results from the phase 2 multicohort LEAP-005 study. Gynecologic Oncology. 186. 182–190. 8 indexed citations
3.
Shapiro, Geoffrey I., Bristi Basu, Anthony B. El-Khoueiry, et al.. (2023). 821TiP Phase I study of ceralasertib (cerala) in combination with AZD5305 in patients (pts) with advanced/metastatic ovarian cancer (OC) previously treated with PARP inhibitors (PARPis). Annals of Oncology. 34. S542–S542. 2 indexed citations
4.
Dayimu, Alimu, Lorena Di Lisio, Shubha Anand, et al.. (2023). Clinical and biological markers predictive of treatment response associated with metastatic pancreatic adenocarcinoma. British Journal of Cancer. 128(9). 1672–1680. 5 indexed citations
5.
Manavaki, Roido, Doreen Lau, Lorna B. Jarvis, et al.. (2020). Detection limit of 89Zr-labeled T cells for cellular tracking: an in vitro imaging approach using clinical PET/CT and PET/MRI. EJNMMI Research. 10(1). 82–82. 13 indexed citations
6.
Harrington, Jennifer, Louise Carter, Bristi Basu, & Natalie Cook. (2018). Drug development and clinical trial design in pancreatico-biliary malignancies. Current Problems in Cancer. 42(1). 73–94. 5 indexed citations
7.
Cook, Natalie, Bristi Basu, D. M. Smith, et al.. (2018). A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma. British Journal of Cancer. 118(6). 793–801. 96 indexed citations
8.
9.
Basu, Bristi, Charlie Gourley, Hani Gabra, et al.. (2016). PISARRO: A EUTROC phase 1b study of APR-246 with carboplatin (C) and pegylated liposomal doxorubicin (PLD) in relapsed platinum-sensitive high grade serous ovarian cancer (HGSOC). Annals of Oncology. 27. vi123–vi123. 6 indexed citations
10.
Basu, Bristi, Emma Dean, M. Puglisi, et al.. (2015). First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014. Clinical Cancer Research. 21(15). 3412–3419. 102 indexed citations
11.
Sayal, Karen, Ioannis Gounaris, Bristi Basu, et al.. (2015). Epirubicin, Cisplatin, and Capecitabine for Primary Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer. International Journal of Gynecological Cancer. 25(6). 977–984. 12 indexed citations
12.
Heidelberger, Sibylle, Giovanna Zinzalla, Dyeison Antonow, et al.. (2013). Investigation of the protein alkylation sites of the STAT3:STAT3 inhibitor Stattic by mass spectrometry. Bioorganic & Medicinal Chemistry Letters. 23(16). 4719–4722. 44 indexed citations
13.
Basu, Bristi, Timothy A. Yap, L. Rhoda Molife, & Johann S. de Bono. (2012). Targeting the DNA damage response in oncology. Current Opinion in Oncology. 24(3). 316–324. 45 indexed citations
14.
Yan, Mengyong, Nourredine Himoudi, Bristi Basu, et al.. (2011). Increased PRAME antigen-specific killing of malignant cell lines by low avidity CTL clones, following treatment with 5-Aza-2′-Deoxycytidine. Cancer Immunology Immunotherapy. 60(9). 1243–1255. 27 indexed citations
15.
Cook, Natalie, Bristi Basu, Swethajit Biswas, et al.. (2010). A phase 2 study of vatalanib in metastatic melanoma patients. European Journal of Cancer. 46(15). 2671–2673. 23 indexed citations
16.
Basu, Bristi & Tim Eisen. (2010). Perspectives in drug development for metastatic renal cell cancer. Targeted Oncology. 5(2). 139–156. 11 indexed citations
17.
Basu, Bristi, et al.. (2010). Newer versus Conventional Methods in the Diagnosis of Malaria: A Comparison. Medical Journal Armed Forces India. 66(2). 129–133. 3 indexed citations
18.
Basu, Bristi, Bhawna Sirohi, & Pippa Corrie. (2009). Systemic therapy for neuroendocrine tumours of gastroenteropancreatic origin. Endocrine Related Cancer. 17(1). R75–R90. 62 indexed citations
19.
Basu, Bristi, et al.. (2009). Angiogenesis in cutaneous malignant melanoma and potential therapeutic strategies. Expert Review of Anticancer Therapy. 9(11). 1583–1598. 19 indexed citations
20.
Prasad, Rajniti, et al.. (2009). The co-existence of CHARGE and myelodysplastic syndrome in a child. BMJ Case Reports. 2009. bcr0520091859–bcr0520091859. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Theresa L. Werner Breakdown of academic impact, for papers by Sharad Ghamande Breakdown of academic impact, for papers by Ramona F. Swaby Breakdown of academic impact, for papers by Yoshiyasu Nakamura Breakdown of academic impact, for papers by Ashiq Masood Breakdown of academic impact, for papers by Dagmar Hess Breakdown of academic impact, for papers by Jane Robertson Breakdown of academic impact, for papers by Stephen Welch Breakdown of academic impact, for papers by Emmanuel Blot Breakdown of academic impact, for papers by Ruth Board
Rankless by CCL
2026